Table 2.
LG268 and CDDO-MA are more potent than erlotinib for preventing lung carcinogenesis in A/J mice injected with vinyl carbamate, 20 wk on diet
| Control | LG268, 60 mg/kg diet | LG268, 30 mg/kg diet | Erlotinib, 200 mg/kg diet | Erlotinib, 100 mg/kg diet | MA, 800 mg/kg diet | |
|---|---|---|---|---|---|---|
| Analysis of inflated lungs | ||||||
| No. mice/group | 23 | 12 | 12 | 12 | 12 | 16 |
| No. tumors/group | 356 | 89 | 144 | 144 | 145 | 146 |
| No. tumors/mouse (% control) | 15.5 ± 1.0 (100) | 7.4 ± 1.0* (48) | 12 ± 0.6 (77) | 12.0 ± 1.1 (77) | 12 ± 0.9 (78) | 9.1 ± 0.7* (59) |
| No. tumors ≤0.5 mm (% of total tumors) | 14 (4) | 25 (28)* | 18 (13) | 19 (13) | 7 (5) | 63 (43)* |
| No. tumors >1 mm (% of total tumors) | 103 (29) | 6 (7)* | 19 (13) | 10 (7)* | 30 (21) | 1 (1)* |
| Analysis of histopathology | ||||||
| Total no. tumors/group | 184 | 33 | 78 | 76 | 83 | 73 |
| Average no. tumors/slide (% control) | 4.2 ± 0.3 (100) | 1.4 ± 0.3* (33) | 3.3 ± 0.4 (78) | 3.2 ± 0.3 (76) | 3.5 ± 0.3 (83) | 2.3 ± 0.3* (55) |
| TTV, mm3 | 559.2 | 45.3 | 134.4 | 131.4 | 196.0 | 52.5 |
| Average tumor size, mm3 (% control) | 3.0 ± 0.3 (100) | 1.4 ± 0.4* (45) | 1.7 ± 0.4* (57) | 1.7 ± 0.4* (57) | 2.4 ± 0.5 (78) | 0.7 ± 0.1* (24) |
| Average tumor burden, mm3/slide (% control) | 12.7 ± 1.5 (100) | 1.9 ± 0.4* (15) | 5.6 ± 1.2* (44) | 5.5 ± 1.0* (43) | 8.2 ± 1.0 (64) | 1.6 ± 0.3* (13) |
| No. low-grade tumors (%) | 25 (13) | 3 (9) | 18 (23) | 23 (30)* | 14 (17) | 35 (48)* |
| No. medium-grade tumors (%) | 51 (28) | 20 (61)* | 27 (35) | 30 (40) | 27 (32) | 20 (27) |
| No. high-grade tumors (%) | 108 (59) | 10 (30)* | 33 (42)* | 23 (30)* | 42 (51) | 18 (25)* |
NOTE: Female A/J mice were injected i.p. with two doses of vinyl carbamate (0.32 mg/mouse), 1 wk apart. One week after the final injection with the carcinogen, mice were fed compounds in diet for 20 wk. Mean ± SE.
*
P < 0.05 versus control.